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Recently, we presented a strategy for analysis of eight biomarkers in human urine to
verify toxic mushroom or Ricinus communis ingestions. However, screening for the
full panel is not always necessary. Thus, we aimed to develop a strategy to reduce
analysis time and by focusing on two sets of analytes. One set (A) for biomarkers of
late-onset syndromes, such as phalloides syndrome or the syndrome after castor
bean intake. Another set (B) for biomarkers of early-onset syndromes, such as
pantherine–muscaria syndrome and muscarine syndrome. Both analyses should be
based on hydrophilic-interaction liquid chromatography coupled with high-resolution
mass spectrometry (MS)/MS (HILIC-HRMS/MS). For A, urine samples were prepared
by liquid–liquid extraction using dichloromethane and subsequent solid-phase
extraction of the aqueous supernatant. For B urine was precipitated using acetoni-
trile. Method A was validated for ricinine and α- and β-amanitin and method B for
muscarine, muscimol, and ibotenic acid according to the specifications for qualitative
analytical methods. In addition, robustness of recovery and normalized matrix factors
to matrix variability measured by urinary creatinine was tested. Moreover, applicabil-
ity was tested using 10 urine samples from patients after suspected mushroom
intoxication. The analytes α- and β-amanitin, muscarine, muscimol, and ibotenic acid
could be successfully identified. Finally, psilocin-O-glucuronide could be identified in
two samples and unambiguously distinguished from bufotenine-O-glucuronide via
their MS2 patterns. In summary, the current workflow offers several advantages
towards the previous method, particularly being more labor-, time-, and cost-
efficient, more robust, and more sensitive.
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1 | INTRODUCTION
Exposure to toxic fungi or plants is an important issue in areas
such as forensics, food safety, and intensive care.1–5 An overview
on relevant syndromes after toxic mushroom intake was provided
by White et al.6 Intoxications by fungi or plants often occur by
accident, when wild-picked toxic mushrooms are consumed after a
mix-up or after an ingestion by toddlers.3,7,8 Furthermore, mush-
rooms like Amanita phalloides or castor beans, the seeds of Ricinus
communis, can be used by intention to attempt suicide or murder
due to their high toxicity.1,9–11 Other mushrooms like Psilocybe
species and Amanita muscaria or Amanita pantherina contain psy-
choactive ingredients, such as psilocybin and psilocin or muscimol
and ibotenic acid, respectively.12 Due to their potential of being
used as a psychoactive drug, they are also relevant in driving under
influence of drugs (DUID) events.13 In particular, Psilocybe species
and their active ingredients are currently gaining attention due to
their promising therapeutic potential in mental disorders and may
be used as pharmaceuticals in the future.14,15 Today, they are still
controlled by legislature in many countries but recent acts of
decriminalizing could increase their availability and popularity.16,17
This demonstrates the need for suitable analytical methods for
specific demands in clinical and forensic toxicology, which can be
applied to detect mushroom toxins or specific biomarkers in com-
plex human or animal samples.
In a recently published study, we presented a validated analytical
strategy based on hydrophilic-interaction liquid chromatography
(LC) coupled with high-resolution mass spectrometry (MS)/MS
(HILIC-HRMS/MS) analysis (termed as “Method R” throughout the
following parts of the manuscript) to identify ricinine, biomarker of
castor bean intoxication, and seven mushroom toxins in urine.18 In
detail, the method included α- and β-amanitin, related to phalloides
syndrome, muscimol and ibotenic acid, related to pantherine–
muscaria syndrome, muscarine, related to muscarine syndrome,
psilocin, related to psilocybin mushroom intoxication, and bufotenine,
related to bufotenine mushroom or Bufo toad intoxication.5,19,20
Besides, bufotenine is discussed as a potential human metabolite of
serotonin, and it should therefore be discriminated from its structural
isomer psilocin.21–23 In the context of intoxication after suspected
consumption of wild fungi, the presence of amatoxins should either
be confirmed or excluded by analysis in order to start a proper
treatment as soon as possible. Even if ingestions of wild mushrooms
lead to neuropsychiatric or cholinergic symptoms, a potential
co-ingestion of other toxic wild-growing fungi, leading to dangerous
late-onset symptoms, should be evaluated. Such a co-ingestion of
A. muscaria and A. phalloides was described in a case report by Garcia
et al.24 However, in many cases of suspected mushroom intoxication,
there is no necessity to cover all above-mentioned analytes in one
analytical run. In case of Ricinus seed or amatoxin intoxication, first
symptoms are observed after 4–10 h and 6–12 h of ingestion, respec-
tively.5,25,26 Therefore, the absence of early-onset (typical up to 2 [–3]
h after ingestion) neuropsychiatric or neurologic/vegetative symptoms
of the other mentioned toxidromes would make the analysis of their
corresponding toxins/biomarkers not necessary.5 Moreover, Psilocybe
fungi brought on the drug market are usually cultivated and not
collected in the forests. Thus, a mix-up or co-ingestion of different
toxic mushrooms of other genera would be unlikely.27,28 Therefore, in
intoxication cases after (suspected) abuse of such mushrooms or
in forensic DUID cases, analyses of the hallucinogens or
corresponding biomarkers might be sufficient.
The aim of the current study was therefore to simplify and further
develop the qualitative analysis of eight biomarkers (α-amanitin,
β-amanitin, bufotenine-O-glucuronide, ibotenic acid, muscarine,
muscimol, psilocin-O-glucuronide, and ricinine; structures shown in
Figure 1) in human urine compared with the previous method.18
Psilocin and bufotenine glucuronide should be included as psilocin-
O-glucuronide showed a higher stability in biosamples amongst others
and as it can be distinguished from bufotenin-O-glucuronide via their
MS2 patterns.18,29,30
A strategy should be developed and validated offering an easier
of workflow and less turnaround time. Applicability should be tested
by analyzing human urine samples obtained from suspected
mushroom intoxication cases. Finally, robustness towards matrix
variability (high-level creatinine) should be evaluated.
2 | EXPERIMENTAL
2.1 | Chemicals and reagents
Ricinine was obtained from Latoxan (Portes-lès-Valence, France),
ibotenic acid from Hello Bio (Bristol, UK), muscimol from Tocris
(Wiesbaden, Germany), α-, β-, and γ-amanitin, and (+)-muscarine
chloride from Sigma-Aldrich (Taufkirchen, Germany), and
L-tryptophan-d5 from Alsachim (Illkirch-Graffenstaden, France), each
as pure substances. Water was purified using a Milli-Q water
purification system (Merck KGaA, Darmstadt, Germany) to reduce its
resistivity to 18.2 MΩ •cm. Methanol (MeOH), ACN, dichloromethane
(DCM), formic acid, and other chemicals were obtained from VWR
(Darmstadt, Germany).
2.2 | Preparation of stock and working solutions
Stock solutions of α-amanitin, β-amanitin, γ-amanitin, (+)-muscarine,
ricinine, and L-tryptophan-d5 were prepared at a concentration of
1000 mg/L in MeOH. Ibotenic acid and muscimol were dissolved in
purified water at 1500 mg/L and 5000 mg/L, respectively. These
stock solutions and all working solutions mentioned hereinafter were
stored at 20C.
2.2.1 | Method A
Working Solution A1 was aqueous and contained α- and β-amanitin,
each 0.5 mg/L. Working Solution A2 consisted of 4.5 mg/L ricinine in
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acetonitrile. The internal standard (IS) working Solution A contained
3.0 mg/L γ-amanitin in MeOH.
2.2.2 | Method B
Analyte working Solution B consisted of ibotenic acid (420 mg/L),
muscimol (200 mg/L), and muscarine (1.2 mg/L) and was prepared
with water. IS working Solution B was prepared by dilution of
L-tryptophan-d5 stock solution to a concentration of 20 mg/L
using MeOH.
2.3 | LC-HRMS/MS apparatus
The instrument was the same as for Method R.18 A Dionex UltiMate
3000 RS ultra-high-performance LC (UHPLC) system (Thermo Fisher
Scientific, Dreieich, Germany) equipped with a quaternary UltiMate
3000 RS pump and an UltiMate 3000 RS autosampler was used, all
controlled by Aria MX 2.2 software (Thermo Fisher Scientific). A
Nucleodur HILIC column (Macherey-Nagel, Düren, Germany),
100  2 mm, 1.8 μm, was coupled to a TF Q-Exactive Focus,
equipped with a heated electrospray ionization II source (HESI-II). The
adopted HESI-II conditions were as follows31: sheath gas, 60 arbitrary
units (AU); auxiliary gas, 10 AU; spray voltage, 4.00 kV; heater tem-
perature, 320C; ion transfer capillary temperature, 320C; and S-lens
RF level, 60.0. External mass calibration was conducted as rec-
ommended by the manufacturer.
2.4 | LC settings
2.4.1 | Method A
Eluent A consisted of 40-mM ammonium formate, solved in a mixture of
98.5% (v/v) MeOH, 1% (v/v) purified water, and 0.5% (v/v) formic acid.
Eluent B was 100% ACN and eluent C purified water. The multistep gra-
dient consisted of six time windows (TWs) as follows: TW 1, step: from
0:00 to 0:20 min, A: kept at 4%, B: kept at 96%; TW 2, ramp: from 0:20
to 8:20 min, A: to 12%, B: to 88%; TW 3, ramp: from 8:20 to 9:20 min,
A: to 28%, B: to 72%; TW 4, ramp: from 9:20 to 12:50 min, A: to 40%,
B: to 60%, C: to 0%; TW 5, step: from 12:50 to 15:20 min, A: kept at
25%, B: kept at 25%, C: kept at 50%; TW 6, step: from 15:20 min to
16:50 min, A: kept at 4%; B: kept at 96%, C kept at 0%; the flow rate
was set to 0.80 ml/min in TW 1, 0.75 ml/min in TW 2, 0.70 ml/min in
TW 3, 0.60 ml/min in TW 4 and 5, and 0.50 ml/min in TW 6. The
injection volume was 5 μl. The elution profile is shown in Figure S1A.
2.4.2 | Method B
Eluent A was MeOH acidified with 2% (v/v) formic acid, Eluent B was
ACN, and eluent C purified water. The gradient consisted of four TWs:
TW 1, step: from 0:00 to 0:20 min, A: kept at 1%, B: kept at 99%; TW
2, ramp: from 0:20 to 8:50 min, A: to 55%; B: to 45%, C: to 0%; TW
3, step: from 8:50 to 11:50 min, A: kept at 25%, B: kept at 25%, C: kept
at 50%; TW 4, step: from 11:50 to 13:20 min, A: kept at 1%; B: kept at
99%, C kept at 0%; the flow rate was set to 0.70 ml/min in TW 1 and
F IGURE 1 Method A structures of analytes and the internal standard (IS): (a) α-amanitin, (b) β-amanitin, (c) ricinine, (d) γ-amanitin (IS). Method
B structures of analytes and the IS: (a) bufotenine-O-glucuronide, (b) psilocin-O-glucuronide, (c) ibotenic acid, (d) muscimol, (e) muscarine,
(f) L-tryptophan-d5 (IS)
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2, 0.50 ml/min in TW 3, and 0.60 ml/min in TW 4. The injection vol-
ume was 5 μl. The elution profile is shown in Figure S1B.
2.5 | MS settings
2.5.1 | Method A
Parameters of full scan experiments: polarity, positive; resolution,
70,000; scan range 1, 110–390 m/z; scan range 2, 890–932 m/z; auto-
matic gain control (AGC) target, 2  105; maximum injection time (IT),
120 ms; microscans, 1; spectrum data type, profile. In the following,
data-dependent MS/MS (dd-MS2) experiments were performed in
discovery mode. An inclusion list containing the exact masses of the
following positively charged analytes was used: α-amanitin (m/z
919.3614), β-amanitin (m/z 920.3455), γ-amanitin (m/z 903.3665),
muscarine (m/z 174.1489), muscimol (m/z 115.0502), ibotenic acid (m/z
159.0400), psilocin/bufotenine (m/z 205.1335), ricinine (m/z 165.0659),
L-tryptophan-d5 (m/z 210.1285), psilocin-d10 (m/z 215.1963),
psilocin-O-glucuronide/bufotenine-O-glucuronide (m/z 381.1656). The
customized tolerance of mass deviations of this inclusion list was set to
5 ppm. The settings for dd-MS2 mode were as follows: resolution,
70,000; isolation window, 3.0 m/z; normalized collision energy (NCE) in
high collision dissociation (HCD) cell, 28%; default charge state, 1; AGC
target, 5  104; maximum IT, 120 ms; loop count, 1; minimum AGC tar-
get, 5  101; dynamic exclusion, 2.0 s; charge exclusion, ≥2; exclude
isotopes, on; spectrum data type, profile.
2.5.2 | Method B
Parameters of full scan experiments: polarity, positive; resolution,
35,000; scan range, 105–390 m/z; AGC target, 1  106; maximum IT,
120 ms; microscans, 1; spectrum data type, profile. In the following, dd-
MS2 experiments were performed in discovery mode. An inclusion list
containing the exact masses of the following positively charged analytes
was used: muscarine (m/z 174.1489), muscimol (m/z 115.0502),
ibotenic acid (m/z 159.0400) psilocin/bufotenine (m/z 205.1335),
L-tryptophan-d5 (m/z 210.1285), psilocin-d10 (m/z 215.1963),
psilocin-O-glucuronide/bufotenine-O-glucuronide (m/z 381.1656). The
customized tolerance of mass deviations of this inclusion list was set to
10 ppm. The settings for the dd-MS2 mode were as follows: resolution,
35,000; isolation window, 1.0 m/z; NCE, 28%; default charge state, 1;
AGC target, 1  105; maximum IT, 160 ms; loop count, 1; minimum
AGC target, 5  101; dynamic exclusion, 2.0 s; charge exclusion, ≥2;
exclude isotopes, on; spectrum data type, profile.
2.6 | Data handling
Data were processed by using Xcalibur Qual Browser 2.2 software
(Thermo Fisher Scientific) was used. The mass tolerance for integra-
tion of peaks was set to 10 ppm.
2.7 | Sample preparation
2.7.1 | Method A
A volume of 1470 μl urine was fortified with 15 μl of working Solution
A1, 10 μl of working Solution A2, and 5 μl of IS Solution A. Patient sam-
ples and blank urine were fortified with 25 μl of a mixture of ACN and
MeOH (40/60, v/v) for volume adjustment to replace working solutions.
Afterwards, the mixture was centrifuged at 10C for 10 min at
21,130  g. Then, 1300 μl of the supernatant (Supernatant A) was
added to 600 μl of DCM and a hydrophilic-phase liquid–liquid extraction
(HP-LLE) was performed during 2 min of shaking and afterwards cen-
trifuged for 10 min at 18,407  g. A volume of 1100 μl of the aqueous
upper phase (Supernatant B) was diluted with 4400 μl of 0.1% formic
acid before solid-phase extraction (SPE) was performed. Strata X-Drug B
33 μm Polymeric Strong Cation cartridges (Phenomenex, Aschaffenburg,
Germany), containing 60 mg of sorbent mass and 3-ml capacity were
preconditioned and equilibrated with 2  1 ml of MeOH and 1 ml of
0.1% formic acid, respectively. Then, the mixture was loaded, followed
by two washing steps, using 1 ml of 1% formic acid and 2  1 ml of
0.1% formic acid, respectively. In the next step, analytes were eluted by
loading 0.6 ml of MeOH in duplicate. This eluate was gently evaporated
at 70C under a stream of nitrogen and reconstituted by 100 μl of
Eluent A of Method A (see Section 2.4.1).
2.7.2 | Method B
A volume of 190-μl urine was fortified with 5 μl of working Solution B
and 5 μl of IS Solution B. Patient samples and blank urine were forti-
fied with 5 μl of purified water for volume adjustment to replace
working Solution B. Afterwards, the mixture was centrifuged at
10C for 10 min at 21,130  g. Then, 100 μl of this supernatant
were added to 500 μl of ACN, followed by 2 min of shaking and 2 min
of centrifugation using 18,407  g. A 500 μl of the resulting
ACN-containing supernatant was evaporated at 60C under a stream
of nitrogen and reconstituted by 100 μl of Eluent A of Method B
(see Section 2.4.2).
2.8 | Method validation
Methods A and B were validated according to the recommendations
for validation of qualitative methods, covering selectivity, carry-over,
matrix effects, and limits of identification (LOIs).31–34 For better com-
parison, all analyzed urine samples in the current validation experi-
ments were the same samples as those for validation of Method R.18
Selectivity was tested by analyzing 10 blank urine samples from dif-
ferent human donors. Analyte carry-over was evaluated by injecting
zero samples after a quality control (QC) sample, spiked with toxins in
high concentrations (ibotenic acid and muscimol, 100 mg/L, each,
muscarine, psilocin, bufotenine, and ricinine, 5 mg/L, each; α- and
β-amanitin, 1 mg/L, each).
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Recovery (RE) and matrix effects (MEs) experiments were con-
ducted by using blank urine samples from six different human
donors, processed in triplicate. RE was determined by comparing
peak areas of the analytes (MH+) spiked into urine samples before
extraction with areas of the extracts of blank samples spiked with
the analytes afterwards. MEs were calculated by comparing peak
areas of spiked extracts with those in neat standards. Coefficients
of variation (CV) of RE and ME were calculated on the means of
the replicates (n = 3) of each individual sample. IS-normalized
matrix factors (MFIS) were calculated as specified in European
Medicines Agency (EMA) guidelines.33 The MF of the IS γ-amanitin
was used to normalize MFs of α- and β-amanitin and ricinine
(Method A), and the MF of the IS L-tryptophan-d5 was used for
muscarine, muscimol, and ibotenic acid (Method B). Analyte con-
centrations spiked into the samples, and extracts are listed in
Table 1. All calculations were performed in Excel 2016 (Microsoft,
Redmond, USA).
LOIs were determined by dilution of QC samples prepared in trip-
licate using pooled blank urine of 10 donors. Those samples were ana-
lyzed in two runs on two consecutive days. The LOI was defined as
the lowest concentration at which the identification of the analytes
was still possible in each analysis according to the identification
criteria.31,35 Both, the accurate mass of the precursor ion must be
detected and the corresponding high-resolution MS2 spectrum or
selected fragment ions must match the reference data and retention
window. Reference spectra can be found in the supporting informa-
tion of Method R.18 The criteria for each analyte are given in Table 1.
2.9 | Estimation of matrix variability robustness
As for validation experiments, the same urine samples were processed
using the methods A, B, and R. The same set of urine samples used for
recovery and matrix effect experiments was extended by three
TABLE 1 Analytes and internal standards (IS) of Methods A and B and their expected retention window (RW), mass spectrometry (MS)
identification criteria, and concentrations in QC samples used for evaluation of recovery (RE) and matrix effects (ME)
Method Compound RW (min) MS-identification criterium QC samples (ng/ml)
Method A α-Amanitin
m/z (MH+) = 919.3614




m/z (MH+) = 920.3455




m/z (MH+) = 903.3665




m/z (MH+) = 165.0659
0.45–0.75 Full dd MS2 spectrum 100
Method B Muscarine
m/z (M+) = 174.1489
0.60–2.2 Full dd MS2 spectrum 100
Muscimol
m/z (MH+) = 115.0502




m/z (MH+) = 159.0400




m/z (MH+) = 210.1285
5.4–7.4 m/z = 192.0957 500
Psilocin-O-glucuronidea
m/z (MH+) = 381.1656
6.0–6.7 Full dd MS2 spectrum
Incl. m/z = 336.1078
Rel. abundance = 0.5%
Bufotenine-O-glucuronidea
m/z (MH+) = 381.1656
5.2–6.2b Full dd MS2 spectrum
Incl. m/z = 336.1078
Rel. abundance = 15%
Abbreviations: QC, quality control; dd, data dependent.
aThe O-glucuronides of psilocin and bufotenine were not included in validation experiments.
bRT determined for incubate of pooled human liver microsomes.18
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selected samples with high urinary creatinine >300 mg/dl. In order to
evaluate RE, ME, and MFIS of the extended sample set (n = 9), those
additional samples were processed like the other six as outlined above
for Methods A and B or as described previously.18 Then, CVs of RE
and MFIS were calculated as described for the extended set and com-
pared against the original set (n = 6). The changes of CVs after exten-
ding the sample set were finally used to compare Methods A and B
against Method R concerning robustness towards matrix variability.
Urinary creatinine was quantified using the P.I.A.2 device (Protzek,
Lörrach, Germany).
2.10 | Applicability
Applicability was tested by analyzing urine samples from subjects
after suspected consumption of toxic mushrooms. These samples had
been sent to the authors' laboratory for regular toxicological analysis.
Urinary creatinine of these samples was determined as mentioned in
Section 2.8.
3 | RESULTS AND DISCUSSION
In clinical toxicology, time-saving comprehensive methods are favor-
able, because they allow fast decision making and a rapid start of a
specific therapy. So far, several analytical methods have been publi-
shed that allow detection of biomarkers of one mushroom intoxica-
tion syndrome or Ricinus seed intoxication in human urine or
plasma.29,36–44 Tomkova et al. developed a method for a simultaneous
determination of α- and β-amanitin and muscarine in urine by
LC-high-resolution (HR)-time-of-flight (TOF) MS.45 Recently, we pres-
ented a comprehensive and validated analytical solution to identify a
total of eight biomarkers of castor bean intoxication, phalloides
syndrome, pantherine–muscaria syndrome, muscarine syndrome,
psilocybin syndrome, and bufotenine intoxication in urine within one
single run.18 The samples were prepared by SPE and urine precipita-
tion performed in parallel and the use of a four-eluent system for
normal-phase chromatography were necessary to realize the aims of
selectivity and earmarked sensitivity for all analytes. However, as
there is not always the need to screen for all biomarkers using such an
extensive method, the method should be simplified by saving cost and
turnaround time while enhancing flexibility in toxicological analysis by
development of two separate methods for biomarker identification of
late- and early-onset syndromes, respectively.
Psilocin is known to be prone to oxidative decomposition due to
effects of light. Furthermore, discrimination against the isobaric
bufotenine via MS2 spectrum alone is not possible. Thus, psilocin-
O-glucuronide was preferred in this study over psilocin as screening
target as it shows higher amounts of excretion (>80% of total
psilocybin), a higher stability, and can be distinguished from
bufotenine-O-glucuronide via their MS2 spectra (Table 1).18,29,30,46,47
Kamata et al. demonstrated that unbound psilocin was excreted more
rapidly from the body than the glucuronide, indicating an extended
detection window for the latter—in their study up to 52 h for plasma
analysis.47 However, psilocin-O-glucuronide and bufotenine-
O-glucuronide were not available as pure standards, and thus, full
method validation could not be performed.
3.1 | Extraction
The sample preparation protocol of Method R was further optimized
and finally separated into SPE (Method A) and precipitation (Method
B).18 The addition of ascorbic acid before and after several extraction
steps to prevent decomposition of psilocin was not necessary any-
more. The intermediate step of HP-LLE after 10 min of cooled centri-
fugation of urine was kept only for Method A to reduce matrix
effects. For Method B, the benefit of LLE before precipitation was
negligible. Furthermore, the SPE protocol of Method A was short-
ened, compared with Method R, as the second elution step with a
mixture of aqueous ammonia/isopropanol/DCM (2/18/80, v/v/v) to
recover psilocin and bufotenine was removed. The thermal stability of
the remaining analytes allowed a faster nitrogen evaporation of the
methanolic eluate of Method A and the ACN-containing supernatant
of Method B at 70C and 60C, respectively, instead of 45C in
Method R.
3.2 | Analysis
The analytes of Method A and B were separated by using two differ-
ent optimized gradients on the same HILIC column (Figures 2 and
S1A,B ). The expected retention windows are listed in Table 1. The LC
gradient could be reduced to a duration of 16:50 min for Method A
and to 13:20 min for Method B, compared with 20:50 min for
Method R.18 To enhance sensitivity of muscimol and ibotenic acid in
Method B, the ionization efficiency of their MH+ ions was improved
by avoiding the use of eluent buffers. While four eluents had to be
used in Method R, a third aqueous eluent was still needed in gradients
of Methods A and B, to keep the column clean from impurities and for
reconstitution of the stationary phase (Figure S1A,B). However, it
might be even possible to work only with the two organic Eluents A
and B by adding an injection for maintenance with an aqueous eluent
after a couple of injections, but this was not thoroughly tested. For
higher MS sensitivity, especially for the amatoxins, the MS2 isolation
window was set to 3.0 m/z. The NCE of 28% used in Method R was
kept for Methods A and B; thus, MS2 spectra are the same as
published previously.18
3.3 | Method validation
Interfering signals that may lead to false identification according to
criteria given in Table 1 were not observed. Analyte recoveries of
Method A (>86%) were higher than of Method B (46%–62%, see
Table 2). Ricinine showed a much higher recovery (106%) than in
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Method R (33%), whereas recoveries of muscarine and muscimol
appeared to be lower than in the referenced method (110% and 68%,
respectively).18 The latter could be the result of muscarine and muscimol
recovery in the SPE fraction of Method R, not existing in Method B.
According to the EMA guidelines, acceptance criteria of CV (MFIS)
are <15%.33 All analytes (see Table 2) but not ricinine (25%, Method
A) and muscarine (31%, Method B) fell below this threshold value,
showing general appropriateness for IS γ-amanitin and L-tryptophan-
d5, to indicate ME (Table 2). As this EMA acceptance limit is given for
quantitative bioanalytical methods, higher variations of ME might be
accepted, as long the sensitivity aimed for the purpose is reached.
LOIs based on previously defined identification criteria are given
in Table 2. They are comparable with other reported LC–MS/MS
methods and sufficient for application in clinical toxicol-
ogy.38,39,41,45,48,49 Compared with Method R, LOIs were the same
except of muscimol and ibotenic acid, which could be reduced from
2000 to 250 ng/ml and from 1500 to 750 ng/ml, respectively.
Usually, stability experiments are mandatory tests in validation of
bioanalytical methods.33 For all analytes and IS, bench-top and auto-
sampler stability tests were already executed in a previous study.18 As
the same laboratory, autosampler, and stock solutions were used,
these tests were not considered necessary anymore. In the former
study, the only analyte that showed low bench-top stability was
psilocin, which neither was included in Method A nor in Method
B. Although slightly different solvents for reconstitution were used in
Methods A and B, we do not recommend exceeding 5 days of storage
in the cooled (10C) autosampler.18
3.4 | Matrix variability robustness and comparison
with Method R
There is a high interindividual and intraindividual variability of concen-
trations of excreted substances in spontaneous urine samples.50 In
F IGURE 2 Extracted fragment ion chromatograms after data dependent MS2 of analytes (MH+) in human urine samples, if available ((a)2a–b;
(b)1a–c, (b)2), matrix-matched quality control (QC) sample (A1) and incubate of human liver microsomes (HLM) ((b)3). Analytes were labeled with
retention times. Mass deviation was set to 10 ppm, NCE = 28; A1, QC blank urine sample, spiked with ricinine; (a)2a–b, Amanita phalloides intake;
(b)1a–c, Amanita muscaria intake; (b)2, Psilocybe sp. intake; (b)3, HLM incubate of bufotenine
TABLE 2 Methods A and B: limits of identification (LOIs), analyte
recoveries (REs) and internal standard-normalized matrix factors
(MFIS) (6 individuals; n = 3)
Compound LOI (ng/ml) RE, % (CV, %) MFIS (CV, %)
α-Amanitin 1 86 (3.9) 1.0a (6.9)
β-Amanitin 1 87 (6.5) 1.2a (11)
γ-Amanitin (IS) 97 (5.8) 0.56b (17)
Ricinine 5 106 (12) 0.19a (25)
Muscarine 5 55 (11) 4.0c (31)
Muscimol 250 46 (19) 0.51c (13)
Ibotenic acid 750 62 (13) 3.4c (7.2)
L-tryptophan-d5 (IS) 38 (8.7) 0.13b (37)
Abbreviations: IS, internal standard; CV, coefficient of variation.
aNormalized by γ-amanitin peak area (method A).
bMFs of IS are not normalized.
cNormalized by L-tryptophan-d5 peak area (method B).
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order to overcome this variance due to changes of urinary filtration
rates, urinary creatinine concentration is commonly used as reference
for interpretation of urinary biomarker concentrations in different
fields, such as occupational health, medicinal research, and foren-
sics.50-53 Despite the amount of urinary creatinine that does not
always reflect urinary excretion, especially when glomerular filtration
rate is reduced, normalization by creatinine is still often used as an
approximation.54 The width of published reference ranges for urinary
creatinine, 28–217 mg/dl for women and 39–259 mg/dl for men,
indicates the extent of the variability.55 In LC–MS-based analytical
methods, the quantity of compounds that can interfere with the
analyte's signal and, thus, the quantity of potential matrix effects
(e.g., ion suppression) would be affected as well. In addition, a high
variability could lead to deviations in analyte recovery due to influ-
ences in stages of sample preparation. Therefore, CVs of both RE and
MFIS of the validation sample set (6 urines, n = 3) and an extended
sample set (9 urines, n = 3) with a wider range of urinary creatinine
were compared. Creatinine values of the validation samples were in
the range of 41–154 mg/dl (determined after the validation
was completed), and those of the additional three were 301, 304, and
>500 mg/dl. For Methods A, B, and R, the REs, MFIS, and
corresponding CVs of the extended set are summarized in Table S1.
The absolute and relative effects of the higher variability of
urinary creatinine by extension of sample set on CVs are specified in
Table 3.
CVs of RE for β-amanitin and ricinine showed a moderate abso-
lute enhancement in the range of 10%–20% for Methods A and R,
apart from other analytes, which showed only minor deviations
(Table 3). The higher variations of REs for β-amanitin could be a rea-
son of increasing pH differences of the diluted urine extract prior to
loading on the SPE columns, because a sufficiently low pH is required
for a high recovery of this analyte. In summary, matrix variability
robustness of Method A or B and Method R based on CVs of RE was
comparable.
In Methods A and B, with exception of ibotenic acid, absolute
changes of CV of MFIS were below 11% under circumstances of a
higher variability of urinary creatinine regarding the extended sample
set (Table 3). In contrast, concerning Method R, absolute changes of
CV of MFIS surpassed 24% for four of the six shared analytes,
α-amanitin, β-amanitin, muscarine, and ibotenic acid. As a result, based
on CVs of RE, matrix variability robustness appears to be higher for
Method A and B compared with those for Method R. This could be
explained in general by a larger amount of matrix compounds in the
extract of Method R that was injected into the LC system and poten-
tially lead to interferences, disturbing the ionization process of
analytes in the following. Because ibotenic acid showed high
absolute and relative changes of CVs of MFIS in both Methods B
and R, L-tryptophan-d5 is probably not the best choice for normaliza-
tion, when this analyte is exposed to high matrix effects.
3.5 | Applicability
Methods A and B were used to analyze 10 urine samples of patients
showing intoxication symptoms after suspected consumption of toxic
fungi (Table 4). Patients 1–4 suffered from phalloides syndrome, and
Patients 6–8 suffered from pantherine–muscaria syndrome after acci-
dentally mixing up wild mushrooms. Patient 5 ingested A. muscaria
and Patients 9 and 10 ingested Psilocybe sp. for recreational purposes.
Analysis results of these urine samples by use of Method R were
already shown with exception of samples of Patients 7 and 8.18 By
using Methods A and B, the same analytes could again be identified in
all cases, except of psilocin and bufotenine. In addition, ibotenic acid
could be identified by Method B in Sample 6, most likely due to higher
TABLE 3 Robustness to matrix variability of Methods A and B compared with a previously published reference method (Method R),18
represented by relative changes of CV values of internal standard-normalized matrix factors (MFIS) and those of analyte recovery, when spiked
QC urine samples from three individuals with elevated creatinine levels (>300 mg/dl) were additionally included to the original setup (six
individuals; n = 3) of matrix effect evaluation. The same urine samples were processed in each method's setup
Compound
Absolute (and relative) changes of analyte recovery CVs (%) Absolute (and relative) changes of MFIS CVs (%)
Methods A and B Method R Methods A and B Method R
α-Amanitin +4.8 (+120) 0.9 (5.9) +7.0 (+100) +30 (+330)
β-Amanitin +16 (+240) +19 (+230) 0.2 (1.4) +24 (+240)
γ-Amanitin (IS)a +0.1 (+2.2) 1.5 (14) +5.4 (+33) +7.0 (+84)
Ricinine +20 (+170) +11 (+55) +11 (+44) 5.4 (17)
Muscarine +2.7 (+26) +2.6 (+30) 0.8 (2.7) +29 (+130)
Muscimol +0.9 (+5.0) 2.1 (7.4) 1.6 (13) +15 (+46)
Ibotenic acid 3.9 (31) 3.9 (10) +22 (+300) +50 (+750)
L-tryptophan-d5 (IS)a 0.4 (5.0) 1.4 (11) +3.6 (+9.7) +32 (+550)
Note: MFs normalized by IS γ-amanitin: α-amanitin, β-amanitin, ricinine. MFs normalized by IS L-tryptophan-d5: muscarine, muscimol, ibotenic acid. MFIS
and analyte recoveries based on six different urine samples of Methods A and B are given in Table 2, and those based on different urine samples of all
methods are given in Table S1
Abbreviations: CV, coefficient of variation; IS, internal standard; n.d., not determined; QC, quality control.
aNot normalized MFs: γ-amanitin, L-tryptophan-d5.
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sensitivity compared with Method R. In the course of this study, urine
samples of Patients 7 and 8 have also been analyzed by using
Method R, and again, all analytes shown in Table 4 could be found. In
Cases 9 and 10, MS2 spectra of the precursor ion at m/z 381.1656
(retention time = 6.4 min) could be identified as psilocin-
O-glucuronide (Table 1 and Figure 2). Bufotenine-O-glucuronide is
expected to elute 0.1–0.2 min later (see Figure 2) and can be
distinguished from psilocin-O-glucuronide via its MS2 pattern (15%
abundance of MS2 fragment ion at 336.1078 in contrast to 0.5%
abundance in the MS2 spectrum of psilocin-O-glucuronide).
Bufotenine-O-glucuronide was generated by pooled human liver
microsomes as described previously.18 However, in cases where
intake of α- and β-amanitin need to additionally be excluded, the more
comprehensive Method R should be used.
4 | CONCLUSIONS
Two time- and cost-saving analytical procedures were developed for
analyzing biomarkers of late-onset and early-onset syndromes in urine
after suspected mushroom or castor bean intoxication. They might
particularly be used in the context of clinical and forensic toxicology,
for example, to support therapeutic decision making. Compared with
the previous method, the total turnaround time and the number of
used eluents could be reduced and the analysis of psilocin- and
bufotenine-O-glucuronides instead of the unstable parent molecules
was introduced. Furthermore, the optimized workflow offers much
easier handling and a higher sensitivity for ibotenic acid and muscimol
as well as being more robust by compensating for high variances
of urinary excretion. The strategy was successfully applied to identify
α- and β-amanitin, muscarine, muscimol, ibotenic acid, and psilocin-
O-glucuronide in human urine samples after suspected ingestion of
the respective mushrooms.
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